ProVise Management Group LLC Has $9.68 Million Holdings in Sanofi $SNY

ProVise Management Group LLC increased its holdings in shares of Sanofi (NASDAQ:SNY) by 3.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 200,396 shares of the company’s stock after purchasing an additional 7,183 shares during the quarter. ProVise Management Group LLC’s holdings in Sanofi were worth $9,681,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Ameritas Advisory Services LLC bought a new stake in Sanofi during the second quarter worth about $28,000. Accent Capital Management LLC acquired a new position in shares of Sanofi during the 1st quarter worth approximately $29,000. Eastern Bank raised its stake in shares of Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock worth $30,000 after purchasing an additional 300 shares in the last quarter. Banque Transatlantique SA acquired a new stake in shares of Sanofi in the 1st quarter valued at approximately $33,000. Finally, Brentview Investment Management LLC bought a new position in shares of Sanofi in the first quarter valued at $42,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently weighed in on SNY. Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a report on Tuesday. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Finally, Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $56.00 to $58.00 in a research note on Monday, September 8th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $62.67.

Sanofi Trading Down 0.4%

Shares of SNY stock opened at $52.14 on Friday. Sanofi has a 12-month low of $44.62 and a 12-month high of $60.12. The company has a market capitalization of $128.03 billion, a PE ratio of 12.21, a price-to-earnings-growth ratio of 1.38 and a beta of 0.49. The firm has a 50 day moving average price of $49.00 and a two-hundred day moving average price of $49.47. The company has a quick ratio of 0.94, a current ratio of 1.06 and a debt-to-equity ratio of 0.16.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 24th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.10. The company had revenue of $14.53 billion for the quarter, compared to analyst estimates of $12.62 billion. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The firm’s quarterly revenue was down 7.5% compared to the same quarter last year. During the same quarter last year, the company earned $2.25 earnings per share. As a group, analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.